OPIOID INDUCED CONSTIPATION TREATMENT MARKET ANALYSIS

Market News

Key Developments

1. Key players in the market are focused on various growth strategies such as gaining product approvals from regulatory authorities, in order to expand their product portfolio. For instance, in March 2017, Shionogi & Co., Ltd, received approval for Symproic (naldemedine) from the U.S. Food and Drugs Administration (FDA).  Symproic will be used for patients suffering from opioid-induced constipation in adults.
2. Key players in the market are focused on various business strategies such as gaining product approvals from regulatory authorities, in order to expand their product portfolio. For instance, in December 2018, Shionogi BV, the European subsidiary of Shionogi & Co., Ltd, received approval for Symproic (naldemedine) from European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP). Symproic is indicated for the treatment of opioid-induced constipation in adults.
3. Major companies in the market are focused on various growth strategies such as merger and acquisition, in order gain competitive edge in the market. For instance, in December 2017, Mallinckrodt plc, a pharmaceutical company, acquired Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, which will include commercial and development assets. Under this acquisition, Mallinckrodt plc will get access to Sucampo’s commercial asset AMITIZA, which is an effective drug for opioid-induced constipation in adult patients.